A Phase 3 interventional study of Benralizumab and Benralizumab in Asthma, sponsored by AstraZeneca. Completed at 178 sites in 15 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2021-04-13.
Sponsored by AstraZeneca · Phase 3, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing benralizumab in Asthma — 3 open to participants now, 4 under way, 2 of them phase 3. benralizumab · Asthma.
Among the 39 studies testing benralizumab in Asthma, this one is the 8th largest by enrollment, is one of 5 that started in 2016, is one of 20 in phase 3, and was the 14th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →3 of the 39 studies testing benralizumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Argentina, Austria and 11 more countries
Ages 6+
University of California, San Diego · Sites in United States
Ages 18–75
Endeavor Health · Sites in United States
Ages 18+
By country, each count listing its studies:
benralizumab: first FDA approval 2017 (FASENRA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 5 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 447 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 128 across the 39 interventional studies. Of the 31 that completed or were terminated, 24 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 39 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
359 studies in Asthma by AstraZeneca: 19 open now, 28 under way, 8 of them phase 3. Of 330 finished, 129 (39%) have results posted.
Among the 359 studies in Asthma by AstraZeneca, this one is the 80th largest by enrollment of the 248 interventional ones that give a count, is one of 16 that started in 2016, is one of 121 in phase 3, and was the 209th registered.
AstraZeneca’s Asthma studies by the year they started, since 1996.
3 of the studies testing benralizumab in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05692180Phase 3AstraZenecaA Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma | 2026-12-23 |
| NCT06385236University of California, San DiegoLeveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping | 2027-06-30 |
| NCT07654842Endeavor HealthFasenra: An Asthma Study | 2027-09-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 39 studies testing benralizumab in Asthma, from their registry updates:
Among AstraZeneca’s 359 in Asthma:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to continue to characterize the safety profile of benralizumab administration and monitor the pharmacodynamic activity of the drug in those asthma patients who remain on treatment for at least 16 weeks and not more than 40 weeks in the predecessor study D3250C00021 (BORA, NCT02258542).
This is an open-label safety extension study designed to evaluate the safety and tolerability of a fixed 30 mg dose of benralizumab administered subcutaneously (SC) in severe asthma patients on inhaled corticosteroid and long-acting β2 agonist (ICS-LABA) therapy with or without chronic oral corticosteroids (OCS) and/or other asthma controllers. All patients will receive active drug on the same dosing regimen they received in BORA (NCT02258542). In order to protect the blind of BORA, patients will remain blinded to treatment regimen allocation until they have completed all end of treatment (EOT) assessments in BORA and signed informed consent for participation in this study, after which treatment allocation will be unblinded to both the investigator and the patient.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Any disorder including but not limited to cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological, psychiatric or major physical impairment that is not stable in the opinion of the Investigator and could:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Benralizumab administered subcutaneously every 4 weeks
Biological: Benralizumab
Benralizumab administered subcutaneously every 8 weeks
Biological: Benralizumab
Benralizumab administered subcutaneously every 4 weeks
Benralizumab administered subcutaneously every 8 weeks
Change From Baseline in Basophils, Full Analysis Set
Change from baseline in hematologic lab parameter of Basophils.
Time frame: From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.
Change From Baseline in Leukocytes, Full Analysis Set
Change from baseline in hematologic lab parameter of Leukocytes.
Time frame: From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.
Change From Baseline in Lymphocytes, Full Analysis Set
Change from baseline in hematologic lab parameter of Lymphocytes.
Time frame: From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.
Change From Baseline in Neutrophils, Full Analysis Set
Change from baseline in hematologic lab parameter of Neutrophils.
Time frame: From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.
Change From Baseline in Monocytes, Full Analysis Set
Change from baseline in hematologic lab parameter of Monocytes.
Time frame: From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.
Change From Baseline in Platelets, Full Analysis Set
Change from baseline in hematologic lab parameter of Platelets.
Time frame: From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.
Change From Baseline in Hematocrit, Full Analysis Set
Change from baseline in hematologic lab parameter of Hematocrit.
Time frame: From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.
Change From Baseline in Erythrocytes, Full Analysis Set
Change from baseline in hematologic lab parameter of Erythrocytes.
Time frame: From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.
Change From Baseline in Hemoglobin, Full Analysis Set
Change from baseline in hematologic lab parameter of Hemoglobin.
Time frame: From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.
Change From Baseline in Alanine Aminotransferase (ALT), Full Analysis Set
Change from baseline in chemistry test ALT.
Time frame: From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.
Change From Baseline in Aspartate Aminotransferase (AST), Full Analysis Set
Change from baseline in chemistry test AST.
Time frame: From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.
Change From Baseline in Bilirubin, Full Analysis Set
Change from baseline in chemistry test Bilirubin.
Time frame: From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.
Number of Participants With Asthma Exacerbations During Study Period
Asthma exacerbation is defined by a worsening of asthma requiring the use of systemic corticosteroids for at least 3 days, and/or an in patient hospitalization, and/or an emergency department or urgent care visit
Time frame: From week 0 to week 184 in study treatment period and through the follow up period (12 weeks from day of last dose). Number and percentage of participants with asthma exacerbation during this period is presented.
Number of Participants Who Had Health Care Encounter (ie, Hospitalization, Emergency Department Visits, Urgent Care Visits, and All Other Outpatient Visits Due to Asthma) During Study Period
Hospitalizations, Emergency department (ED) visits, urgent care visits and all other outpatient visits due to asthma
Time frame: From week 0 to week 184 in study treatment period and through the follow up period (12 weeks from day of last dose). Number and percentage of participants with health care encounters during this period is presented.
Change of Blood Eosinophils Count
Change from Baseline to End of Treatment in blood eosinophils count.
Time frame: From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.
Number of Participants With Anti-drug Antibodies (ADA) Responses During the Study
Assessments for the presence of ADA and neutralizing antibody (nAb) throughout study
Time frame: From week 0 to week 184 in study treatment period and plus 12 weeks follow up period
Duration of Exposure
Duration of exposure
Time frame: From week 0 to week 184 in study treatment period
447 patients enrolled in MELTEMI, 1 patient from Czech Republic was not treated, thus 446 patients received at least 1 dose of IP. Among these treated participants, 347 were from studies SIROCCO(NCT01928771)/CALIMA(NCT01914757) and 99 were from study ZONDA(NCT02075255).
| Milestone | Benra 30 mg q.4 Weeks | Benra 30 mg q.8 Weeks |
|---|---|---|
| Started | 220 | 226 |
| Treated | 220 | 226 |
| Completed | 189 | 195 |
| Not completed | 31 | 31 |
| Withdrew: Eg. no treatment efficacy on asthma | 5 | 4 |
| Withdrew: Withdrawal by subject | 10 | 13 |
| Withdrew: Site terminated by sponsor | 2 | 0 |
| Withdrew: Pregnancy | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 6 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Development of study-specific withdrawal criteria | 8 | 3 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Adverse event | 3 | 4 |
Change from baseline in hematologic lab parameter of Basophils.
| 10^9 cells/L | Benra 30 mg q.4 Weeks | Benra 30 mg q.8 Weeks | Total |
|---|---|---|---|
| Change From Baseline in Basophils, Full Analysis Set | 0.014 ± 0.0229 | 0.012 ± 0.0243 | 0.013 ± 0.0236 |
Change from baseline in hematologic lab parameter of Leukocytes.
| 10^9 cells/L | Benra 30 mg q.4 Weeks | Benra 30 mg q.8 Weeks | Total |
|---|---|---|---|
| Change From Baseline in Leukocytes, Full Analysis Set | -0.254 ± 2.0446 | -0.498 ± 1.7217 | -0.377 ± 1.8896 |
Change from baseline in hematologic lab parameter of Lymphocytes.
| 10^9 cells/L | Benra 30 mg q.4 Weeks | Benra 30 mg q.8 Weeks | Total |
|---|---|---|---|
| Change From Baseline in Lymphocytes, Full Analysis Set | -0.098 ± 0.5479 | -0.142 ± 0.6544 | -0.121 ± 0.6038 |
Change from baseline in hematologic lab parameter of Neutrophils.
| 10^9 cells/L | Benra 30 mg q.4 Weeks | Benra 30 mg q.8 Weeks | Total |
|---|---|---|---|
| Change From Baseline in Neutrophils, Full Analysis Set | -0.237 ± 1.8765 | -0.392 ± 1.4802 | -0.315 ± 1.6866 |
Change from baseline in hematologic lab parameter of Monocytes.
| 10^9 cells/L | Benra 30 mg q.4 Weeks | Benra 30 mg q.8 Weeks | Total |
|---|---|---|---|
| Change From Baseline in Monocytes, Full Analysis Set | 0.055 ± 0.1835 | 0.056 ± 0.1766 | 0.055 ± 0.1798 |
Change from baseline in hematologic lab parameter of Platelets.
| 10^9 cells/L | Benra 30 mg q.4 Weeks | Benra 30 mg q.8 Weeks | Total |
|---|---|---|---|
| Change From Baseline in Platelets, Full Analysis Set | 9.1 ± 41.72 | 11.9 ± 36.13 | 10.5 ± 38.98 |
Change from baseline in hematologic lab parameter of Hematocrit.
| [ratio] | Benra 30 mg q.4 Weeks | Benra 30 mg q.8 Weeks | Total |
|---|---|---|---|
| Change From Baseline in Hematocrit, Full Analysis Set | -0.002 ± 0.0269 | -0.003 ± 0.0260 | -0.003 ± 0.0264 |
Change from baseline in hematologic lab parameter of Erythrocytes.
| 10^12 cells/L | Benra 30 mg q.4 Weeks | Benra 30 mg q.8 Weeks | Total |
|---|---|---|---|
| Change From Baseline in Erythrocytes, Full Analysis Set | -0.008 ± 0.2922 | -0.054 ± 0.2614 | -0.031 ± 0.2776 |
Change from baseline in hematologic lab parameter of Hemoglobin.
| g/L | Benra 30 mg q.4 Weeks | Benra 30 mg q.8 Weeks | Total |
|---|---|---|---|
| Change From Baseline in Hemoglobin, Full Analysis Set | 2.6 ± 8.92 | 1.2 ± 8.37 | 1.9 ± 8.66 |
Change from baseline in chemistry test ALT.
| ukat/L | Benra 30 mg q.4 Weeks | Benra 30 mg q.8 Weeks | Total |
|---|---|---|---|
| Change From Baseline in Alanine Aminotransferase (ALT), Full Analysis Set | 0.007 ± 0.2060 | 0.004 ± 0.2118 | 0.005 ± 0.2086 |
Change from baseline in chemistry test AST.
| ukat/L | Benra 30 mg q.4 Weeks | Benra 30 mg q.8 Weeks | Total |
|---|---|---|---|
| Change From Baseline in Aspartate Aminotransferase (AST), Full Analysis Set | -0.021 ± 0.1258 | -0.018 ± 0.1280 | -0.020 ± 0.1267 |
Change from baseline in chemistry test Bilirubin.
| umol/L | Benra 30 mg q.4 Weeks | Benra 30 mg q.8 Weeks | Total |
|---|---|---|---|
| Change From Baseline in Bilirubin, Full Analysis Set | -0.451 ± 3.0980 | -0.297 ± 3.3972 | -0.374 ± 3.2486 |
Asthma exacerbation is defined by a worsening of asthma requiring the use of systemic corticosteroids for at least 3 days, and/or an in patient hospitalization, and/or an emergency department or urgent care visit
| Participants | Benra 30 mg q.4 Weeks | Benra 30 mg q.8 Weeks | Total |
|---|---|---|---|
| Number of Participants With Asthma Exacerbations During Study Period | 96 | 97 | 193 |
Hospitalizations, Emergency department (ED) visits, urgent care visits and all other outpatient visits due to asthma
| Participants | Benra 30 mg q.4 Weeks | Benra 30 mg q.8 Weeks | Total |
|---|---|---|---|
| Number of Participants Who Had Health Care Encounter (ie, Hospitalization, Emergency Department Visits, Urgent Care Visits, and All Other Outpatient Visits Due to Asthma) During Study Period | 25 | 28 | 53 |
Change from Baseline to End of Treatment in blood eosinophils count.
| cell/uL | Benra 30 mg q.4 Weeks | Benra 30 mg q.8 Weeks | Total |
|---|---|---|---|
| Change of Blood Eosinophils Count | 12.3 ± 50.24 | -12.9 ± 212.51 | -0.5 ± 155.68 |
Assessments for the presence of ADA and neutralizing antibody (nAb) throughout study
| Participants | Benra 30 mg q.4 Weeks | Benra 30 mg q.8 Weeks | Total |
|---|---|---|---|
| Positive at any visit | 19 | 28 | 47 |
| Both baseline and post-baseline positive | 11 | 17 | 28 |
| Only post-baseline positive | 7 | 10 | 17 |
| ADA Persistently Positive | 12 | 21 | 33 |
| ADA Transiently Positive | 6 | 6 | 12 |
| Only baseline positive | 1 | 1 | 2 |
| nAb positive | 13 | 24 | 37 |
| nAb positive in ADA positive participants | 13 | 24 | 37 |
Duration of exposure
| months | Benra 30 mg q.4 Weeks | Benra 30 mg q.8 Weeks | Total |
|---|---|---|---|
| Duration of Exposure | 26.35 ± 10.112 | 25.36 ± 9.939 | 25.85 ± 10.026 |
Collected over All participants completed treatment period up to Week 184.. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Benra 30 mg q.4 Weeks | 1/220 (0.5%) | 44/220 (20%) | 169/220 (76.8%) |
| Benra 30 mg q.8 Weeks | 0/226 (0%) | 47/226 (20.8%) | 145/226 (64.2%) |
| Event | Benra 30 mg q.4 Weeks | Benra 30 mg q.8 Weeks |
|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 9/220 | 13/226 |
| InfluenzaInfections and infestations | 3/220 | 0/226 |
| AstheniaGeneral disorders | 2/220 | 0/226 |
| Lower limb fractureInjury, poisoning and procedural complications | 2/220 | 0/226 |
| PneumoniaInfections and infestations | 1/220 | 2/226 |
| Limb injuryInjury, poisoning and procedural complications | 0/220 | 2/226 |
| Aortic valve stenosisCardiac disorders | 1/220 | 0/226 |
| Coronary artery occlusionCardiac disorders | 1/220 | 0/226 |
| Left ventricular failureCardiac disorders | 1/220 | 0/226 |
| CataractEye disorders | 1/220 | 1/226 |
| Event | Benra 30 mg q.4 Weeks | Benra 30 mg q.8 Weeks |
|---|---|---|
| NasopharyngitisInfections and infestations | 67/220 | 64/226 |
| HeadacheNervous system disorders | 32/220 | 21/226 |
| Viral upper respiratory tract infectionInfections and infestations | 29/220 | 19/226 |
| HypertensionVascular disorders | 14/220 | 24/226 |
| BronchitisInfections and infestations | 23/220 | 22/226 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 16/220 | 20/226 |
| SinusitisInfections and infestations | 17/220 | 10/226 |
| Upper respiratory tract infectionInfections and infestations | 14/220 | 8/226 |
| Acute sinusitisInfections and infestations | 13/220 | 8/226 |
| Bronchitis bacterialInfections and infestations | 12/220 | 9/226 |
Full analysis set is defined to include subjects who received at least 1 dose of investigational product (IP).
| Age, Continuous(Years) | Benra 30 mg q.4 Weeks | Benra 30 mg q.8 Weeks | Total |
|---|---|---|---|
| Mean | 53.5 ± 12.00 | 53.0 ± 11.64 | 53.2 ± 11.81 |
| Sex: Female, Male(Participants) | Benra 30 mg q.4 Weeks | Benra 30 mg q.8 Weeks | Total |
|---|---|---|---|
| Female | 140 | 144 | 284 |
| Male | 80 | 82 | 162 |
| Race/Ethnicity, Customized(Participants) | Benra 30 mg q.4 Weeks | Benra 30 mg q.8 Weeks | Total |
|---|---|---|---|
| White | 204 | 206 | 410 |
| Black or African | 9 | 13 | 22 |
| American Asian | 5 | 3 | 8 |
| Other | 2 | 4 | 6 |
Showing the first 100 of 178 sites across 15 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Jun 2016 to primary completion in Jun 2020, 47 months.
Results were first posted in Apr 2021, 9 months after primary completion.
Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 47 months is above that.
Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Benralizumab